A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Abstract
Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple agents targeting both canonical and the β-catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · cited 2×
“For example, genetic mutations of Wnt signaling in colorectal cancer (CRC) are observed in more than 90% of patients and are well-known cancer-driving alterations [25,26].”
BackgroundMutations affecting segment number and polarity in Drosophila
Nüsslein-Volhard, C., & Wieschaus, E. (1980) · Nature · doi:10.1038/287795a0 · Cited by 4,370
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Nusse, R., & Varmus, H. E. (1982) · Cell · doi:10.1016/0092-8674(82)90409-3 · Cited by 1,863 · cited 1×
“Concurrently, Int-1, a mammalian wingless homolog, was identified as a driver gene for malignancy when its transcriptional activation was induced by the murine mammary tumor virus [2].”
BackgroundGarzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Cited by
Current advances and development strategies of orally bioavailable PROTACs
Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 91
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Additionally, recently developed technologies are currently being explored to inhibit Wnt signaling, such as proteolysis-targeting chimeras and molecular glue degraders, antibody–drug conjugates, and antisense oligonucleotides [195].”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Multiple agents targeting both canonical and the β -catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
BackgroundLi, C., Furth, E. E., Rustgi, A. K., & Klein, P. S. (2023) · Cells · doi:10.3390/cells12182256 · Cited by 33
Structural and Functional Insights into Dishevelled-Mediated Wnt Signaling
Wang, L., Zhu, R., Wen, Z., Fan, H., Norwood-Jackson, T., Jathan, D., & Lee, H. (2024) · Cells · doi:10.3390/cells13221870 · Cited by 25
Metadata
- Authors
- Park, W.-J., & Kim, M. J.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Kim, Moon Jong
- ORCID
- Kim, Moon Jong
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-04-08
- Volume
- 12
- Issue
- 8
- Pages
- 1110
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10136927
- OpenAlex
- W4363648015
- Cited by
- 57
- References
- 188
- Citations by year
- 2026: 18 · 2025: 13 · 2024: 20 · 2023: 6
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gachon University (GCU-202110420001, NRF-2022R1F1A1074582)
- Korean government (MSIT) (GCU-202110420001, NRF-2022R1F1A1074582)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- Wnt signaling, undruggable targets, cancer therapy, Wnt inhibitors, PROTACs, molecular glues, antibody-drug conjugates, antisense oligonucleotides, clinical trials
- MeSH terms
- Cell Transformation, Neoplastic, Humans, Neoplasms, Stem Cells, Wnt Signaling Pathway, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. https://app.cochat.ai/papers/10.3390/cells12081110
- The paper
- Park, W.-J., & Kim, M. J. (2023). A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells. https://doi.org/10.3390/cells12081110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.